The research group Preclinical Metabolomics aims to investigate metabolic heterogeneity in tumours and their metastases using technologies developed at ISAS. Based on questions from the Department of Dermatology at University Hospital Essen, the group works with mouse models, in vitro models such as cell cultures as well as patient samples, and investigates these using mass spectrometry (MS) and MALDI imaging MS, for example. The translation of the results into the clinic, known as the ‘bench to bedside’ principle, is an essential part of this: in the long term, the scientists want to use the findings to identify new and targeted therapies that address metabolic changes in cancer cells during therapy or metastasis.
